Immunologische Risikopatienten – Diagnostik und Therapie vor und nach Nierentransplantation

Im Szenario der Nierentransplantation lassen sich durch eine verbesserte immunologische Diagnostik (hoch) immunisierte Patienten zunehmend identifizieren. In diesem Beitrag wird der aktuelle Stand in Diagnostik und Therapie dieser Patientengruppe analysiert und es werden die Grenzen derzeitiger Therapieansätze dargestellt.

Kidney recipients with (high) immunological risk are increasingly identified based on improved immunological diagnostics. The state of the art concerning diagnostics, stratification of risk and therapeutic options of this patient group as well as limitations of the current therapeutic approach is analyzed.

Key words

immunological risk patients - diagnostics - therapy - renal transplantation - immunosuppression

• Literatur

• 1 Takemoto SK, Terasaki PI, Gjertson DW, Cecka JM. Twelve years' experience with national sharing of HLA-matched cadaveric kidneys for transplantation. N Engl J Med 2000; 343: 1078-1084
• 2 Hüser N, Matevossian E, Schmidbauer P et al. Calculated withdrawal of low-dose immunosuppression based on a detailed immunological monitoring after kidney transplantation between monocygotic twins. Transpl Immunol 2009; 22: 38-43
• 3 Cecka JM, Terasaki PI. Living donor kidney transplants: superior success rates despite histoincompatibilities. Transplant Proc 1997; 29: 203-203
• 4 Genberg H, Kumlien G, Wennberg L et al. AB0-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up. Transplantation 2008; 85: 1745-1754
• 5 Mulley WR, Kanellis J. Understanding crossmatch testing in organ transplantation: a case-based guide for the general nephrologist. Nephrology (Carlton) 2011; 16: 125-133
• 6 Lachmann N, Todorova K, Schulze H, Schönemann C. Systematic comparison of four cell- and Luminex-based methods for assessment of complement-activating HLA antibodies. Transplantation 2013; 95: 694-700
• 7 Taid BD, Süsal C, Gebel HM et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013; 95: 19-47
• 8 Bielmann D, Hönger G, Lutz D et al. Pretransplant risk assessment in renal allograft recipients using virtual crossmatching. Am J Transplant 2007; 7: 626-632
• 9 Heeger PS, Greenspan NS, Kuhlenschmidt S et al. Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol 1999; 163: 2267-2275
• 10 Claas FH, Rahmel A, Doxiadis II. Enhanced kidney allocation to highly sensitized patients by the acceptable mismatch program. Transplantation 2009; 88: 447-452
• 11 Montgomery RA, Phil D, Lonze BE et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365: 318-326